3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
88
Carcinoma, Non-Small-Cell Lung
86
Multiple Myeloma
73
Prostatic Neoplasms
63
Neoplasms
55
Colorectal Neoplasms
46
Lymphoma
42
Squamous Cell Carcinoma of Head and Neck
41
Leukemia, Myeloid, Acute
41
Lung Neoplasms
39
Pancreatic Neoplasms
32
Neoplasm Metastasis
32
Carcinoma, Hepatocellular
31
Ovarian Neoplasms
30
Lymphoma, Large B-Cell, Diffuse
29
Carcinoma, Renal Cell
29
Urinary Bladder Neoplasms
28
Lymphoma, Non-Hodgkin
27
Melanoma
26
Head and Neck Neoplasms
26
Hematologic Neoplasms
25
Triple Negative Breast Neoplasms
24
Sarcoma
23
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Hodgkin Disease
23
Leukemia, Lymphocytic, Chronic, B-Cell
22
Glioma
22
Stomach Neoplasms
20
Myelodysplastic Syndromes
20
Lymphoma, Mantle-Cell
19
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
High-Risk Localized Prostate Cancer
×
30 days
×
Clear all
NCT07450599
2026-05-13
CHINANEO
Bayer
Phase 2
Recruiting
250 enrolled